Will Rousmaniere
Director of Finance/CFO at ANALOGIC CORPORATION
Profile
William Rousmaniere is currently the Chief Financial Officer, Secretary & Treasurer at Analogic Corp.
and Lundbeck Seattle BioPharmaceuticals, Inc. He previously worked as the Director-Finance, Precision Motion & Technologies at Novanta, Inc. Mr. Rousmaniere completed his undergraduate degree at Cornell University and holds an MBA from The Leonard N Stern School of Business.
Will Rousmaniere active positions
| Companies | Position | Start |
|---|---|---|
| ANALOGIC CORPORATION | Director of Finance/CFO | 2018-06-21 |
| ALDER BIOPHARMACEUTICALS, INC. | Director of Finance/CFO | - |
Former positions of Will Rousmaniere
| Companies | Position | End |
|---|---|---|
| NOVANTA INC. | Corporate Officer/Principal | - |
Training of Will Rousmaniere
| The Leonard N Stern School of Business | Masters Business Admin |
| Cornell University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| NOVANTA INC. | Electronic Technology |
| Private companies | 2 |
|---|---|
Analogic Corp.
 Analogic Corp. Medical SpecialtiesHealth Technology Analogic Corp. engages in the business of designing, development manufacturing, and supporting technically advanced and cost-effective imaging and detection, and power and automation solutions for security, healthcare, and other high-end industrial markets. The firm is also involved in the innovation in the field of computed tomography. The company was founded by Bernard Marshall Gordon on November 27, 1967 and is headquartered in Peabody, MA. | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
- Stock Market
- Insiders
- Will Rousmaniere
